ANIKA THERAPEUTICS - KURSVERFALL GERECHTFERTIGT? - 500 Beiträge pro Seite

[Maiestro]

ANIKA THERAPEUTICS - KURSVERFALL GERECHTFERTIGT?

Noch vor nicht allzu langer Zeit stand die Aktie des US-amerikanischen Unternehmens Anika Therapeutics (WKN 889 120), welches therapeutische Produkte und Geräte zum Schutz und zur Heilung von Knochen, Knorpel und Gewebe entwickelt und produziert, bei etwa 12 Euro und die Marktkapitalisierung betrug 120 Millionen Euro.

Doch die Zeiten haben sich geändert, der Kurs brach ein, nachdem veröffentlicht wurde, dass ein sich in Phase drei befindliches Produkt als negativ herausgestellt hat, zudem trat ein Vorstandsmitglied zurück. Außerdem führt die SEC Untersuchungen durch, um zu prüfen, ob die veröffentlichte Bilanz der Richtigkeit entspricht!

Für das Jahr ´97 hat das Unternehmen einen Umsatz von 12.980.000 Euro angegeben, für ´98 14.412.000 Euro und für ´99 einen Umsatz von 14.640.000 Euro. Hier noch die Gewinnserie: 97 = 0,48; 98 = 0,37; 99 = -0,26; 00(e) = 0,16; 01 (e) = 0,41. [Die Angaben sind pro Aktie angeben!] Das erwartete KGV für 2000 liegt bei niedrigen 11,71, eher Branchenunüblich! Branchenunüblich ist auch, dass das Unternehmen bereits Gewinne erwirtschaftet!

Nun stellt sich die Frage, ob der Kursabschlag gerechtfertigt ist? Immerhin musste der Wert um mehr als 80 % abgeben!

Was meint Ihr dazu? Der Wert ist zwar noch relativ unbekannt, aber gerade deshalb könnte es sich möglicherweise lohnen ihn im Depot zu haben!

Maiestro

[Maiestro]

ANIKA THERAPEUTICS REPORTS UNFAVORABLE ORTHOVISC® CLINICAL TRIAL RESULTS

WOBURN, MA - May 30, 2000 - Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that an initial analysis of results from its recently completed Phase III clinical trial of ORTHOVISC®, its product for treatment of osteoarthritis of the knee, did not show sufficient efficacy to support the filing of a pre-market approval (PMA) application to obtain U.S. Food and Drug Administration (FDA) approval.

"We are disappointed that the results from the study did not achieve the primary efficacy end-point, a measure of pain reduction," said J. Melville Engle, chairman, president and chief executive officer. "We will proceed with a complete analysis of the trial, including safety data, which is not yet available. However, these results indicate that additional clinical data would be necessary to demonstrate the effectiveness required for PMA submission and FDA approval." Engle added that the company must evaluate results in depth before making any decisions about whether to conduct additional clinical trials.

The company completed its ORTHOVISC Phase III clinical trial on February 28, 2000. The study, which consisted of 385 patients with osteoarthritis of the knee, was conducted with rheumatologists and orthopedic surgeons at 22 centers in the U.S. and Canada. Patients enrolled in the study were followed out to six months following the treatment regimen of three injections over a two-week period. The primary efficacy endpoint of the trial is a measure of pain reduction as compared with a saline control. This trial represents Anika`s second attempt to obtain U.S. regulatory approval for ORTHOVISC. In October 1998, the company received a letter from the FDA requesting additional data to support an earlier PMA application.

According to the company`s distribution agreement for ORTHOVISC with Zimmer, Inc., Zimmer may terminate the agreement if ORTHOVISC is not approved by the FDA by January 1, 2001. The company cannot provide any assurance that Zimmer will not seek to terminate the agreement or renegotiate the agreement on terms less favorable to the company. Upon FDA approval, the Zimmer distribution agreement provides for a $2.5 million milestone payment and increased minimum purchases by Zimmer. However, based on the results of the recently completed Phase III clinical trial, there can be no assurances that the company will be able to earn the milestone payment or that Zimmer will be subject to the increased minimum purchase requirements.

Engle noted that the company intends to continue pursuing its product development strategy in the field of tissue repair, protection and healing. As of March 31, 2000, Anika had cash and investments of approximately $19.8 million. ORTHOVISC is currently approved for sale in Europe, Canada and other countries and has been sold in various countries since 1995. In addition, company revenue includes ongoing sales of AMVISC® and AMVISC® Plus, products for ophthalmic surgery, to Bausch & Lomb Surgical.

The company also announced that it has been informed that the Securities and Exchange Commission (SEC) has issued a formal order of investigation and has required the company to provide further information in connection with certain revenue recognition matters. These matters, relating to the company`s historical accounting for sales of its product under a long-term supply and distribution agreement, were the subject of the company`s previous March 15, 2000 disclosure concerning an informal SEC inquiry and the restatement of results for 1998 and the first three quarters of 1999. The company has been cooperating fully with the SEC and intends to continue its cooperation.

Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products and devices intended to promote the repair, protection and healing of bone, cartilage and soft tissue. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. In addition to ORTHOVISC®, a treatment for osteoarthritis of the knee (not approved for sale in the U.S.), Anika markets HYVISC® in the U.S. for the treatment of equine osteoarthritis through Boehringer Ingelheim Vetmedica, Inc. and manufactures AMVISC® and AMVISC® Plus, HA viscoelastic products for ophthalmic surgery, for Bausch & Lomb Surgical. Therapies currently under development include INCERT®, a family of HA products designed to prevent post-surgical adhesions. Anika is also collaborating with Orquest, Inc. to manufacture OSSIGEL®, an injectable formulation of basic fibroblast growth factor combined with HA designed to accelerate the healing of bone fractures, which is also under development.

The statements made in this press release which are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements involve known and unknown risks, uncertainties and other factors. The words "believe," "will," "would," "expect," "anticipate," "intend," "estimate" and other expressions which are predictions of or indicate future events and trends and which do not relate to historical matters identify forward-looking statements. The Company`s actual results could differ materially from any anticipated future results, performance or achievements described in the forward-looking statements as a result of a number of factors, which include the results of its research and development efforts and timing of regulatory approval. There can be no assurances that: (i) further analysis of the clinical data or any additional clinical data will support the efficacy of ORTHOVISC®, (ii) the Company will undertake any additional clinical trials of ORTHOVISC, (iii) it will be able to successfully complete an additional clinical trial or (iv) additional clinical trials will support a PMA application and/or FDA approval in a timely manner or at all. There can be no assurances as to the impact that the timing or lack of FDA approval will have on the Zimmer Distribution Agreement. Furthermore, there can be no assurance that Zimmer will place additional orders in 2000 or that Zimmer will not terminate the Zimmer Distribution Agreement in accordance with its terms. In addition, there can be no assurance that any delay in receiving any such approvals will not adversely affect the Company`s competitive position. In particular, there can be no assurance that the Company and/or Zimmer will obtain European or other reimbursement approvals or if such approvals are obtained they will be obtained on a timely basis or at a satisfactory level of reimbursement. Moreover, there can be no assurances that the Company`s investments in the clinical research and product development in OSSIGEL® and INCERT® will lead to viable products or revenue growth. Certain other factors that might cause the Company`s actual results to differ materially from those in the forward-looking statements include those set forth under the headings "Business," "Risk Factors and Certain Factors Affecting Future Operating Results" and "Management`s Discussion and Analysis of Financial Condition and Results of Operations" in the Company`s Annual Report on Form 10-K for the year ended December 31, 1999, as well as those described in the Company`s other SEC filings.

Contact:

Anika Therapeutics, Inc.
[phone]
Pondel Parsons & Wilkinson
Susan Klein, [phone]
Robert Whetstone, [phone]

[Maiestro]

Das war die Meldung zum Scheitern des Produktes in Phase III!

Maiestro

[Maiestro]

Jetzt kommen die Quartalszahlen dieses Jahres!

Maiestro

[Maiestro]

ANIKA THERAPEUTICS REPORTS FIRST QUARTER RESULTS

WOBURN, Mass.-April 27, 2000-Anika Therapeutics, Inc. (NASDAQ:ANIK) today reported revenue for the first quarter ended March 31, 2000 of $2,721,000 compared with $3,336,000 for the first quarter of 1999. The company recorded a net loss for the quarter of $564,000, or $.06 per diluted share, compared with a net loss of $3,169,000, or $.31 per diluted share, for the same period last year. As previously reported, results for the first quarter of 1999 included a charge of $3,625,000, or $.36 per diluted share, for the cumulative effect of a change in accounting principle relating to revenue recognition for non-refundable fees. Income before the cumulative effect of the accounting change in the first quarter of 1999 was $456,000, or $.05 per diluted share.

According to J. Melville Engle, chairman, president and chief executive officer, revenue for the quarter was impacted by fewer ORTHOVISC® orders from Biomeks Pharmaceuticals, Anika`s distributor in Turkey. "First quarter 2000 shipments were reduced because of higher year-end 1999 in-country stocking levels following the mid-1999 earthquake," Engle said.

Research and development costs for the quarter increased to $1,314,000 compared with $708,000 for the same period last year, primarily due to costs associated with the completion of U.S. Phase III clinical trials for ORTHOVISC. Selling, general and administrative costs in the first quarter of 2000 increased $255,000 compared with the first quarter of 1999, primarily due to costs associated with year-end 1999 corporate matters.

About Anika Therapeutics

Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products and devices intended to promote the repair, protection and healing of bone, cartilage and soft tissue. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. In addition to ORTHOVISC®, a treatment for osteoarthritis of the knee (not approved for sale in the U.S.), Anika markets HYVISC® in the U.S. for the treatment of equine osteoarthritis through Boehringer Ingelheim Vetmedica, Inc. and manufactures AMVISCTM and AMVISCTMPlus, HA viscoelastic products for ophthalmic surgery, for Bausch & Lomb Surgical. Therapies currently under development include INCERT®, a family of HA products designed to prevent post-surgical adhesions. Anika is also collaborating with Orquest, Inc. to manufacture Ossigel®, an injectable formulation of basic fibroblast growth factor combined with HA designed to accelerate the healing of bone fractures.

The statements made in this press release which are not statements of historical fact are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. Forward-looking statements involve known and unknown risks, uncertainties and other factors. The words "believe," "expect," "anticipate," "intend," "estimate," and other expressions which are predictions of or indicate future events and trends and which do not relate to historical matters identify forward-looking statements. The Company`s actual results could differ materially from any anticipated future results, performance or achievements described in the forward-looking statements as a result of a number of factors, which include the demand for the Company`s products, the clinical results of its research and development efforts and the timing of regulatory approvals. There can be no assurances that the clinical data from the ORTHOVISC trial will be released on a timely basis, or at all, or that such data will support the efficacy of ORTHOVISC. Furthermore, there can be no assurances that the Company will be able to obtain regulatory approvals or successfully market any of its therapies currently under development. Certain other factors that might cause the Company`s actual results to differ materially from those in the forward-looking statements include those set forth under the headings "Business," "Risk Factors and Certain Factors Affecting Future Operating Results" and "Management`s Discussion and Analysis of Financial Condition and Results of Operations" in the Company`s Annual Report on Form 10-K for the year ended December 31, 1999 and filed with the Securities and Exchange Commission.





Anika Therapeutics, Inc.



Balance Sheets as of, March 31, 2000 December 31, 1999
(Unaudited)
ASSETS

Current assets:
Cash and cash equivalents $8,946,312 $6,440,705
Short-term investments 5,159,546 8,184,870
Accounts receivable 1,811,927 2,106,452
Inventories 6,792,994 5,493,701
Prepaid expenses 475,183 721,206

Total current assets 23,185,962 22,946,934

Property and equipment 8,207,190 8,116,233
Less accumulated depreciation 4,802,221 4,587,692
Net property and equipment 3,404,969 3,528,541

Long-term investments 5,646,465 5,558,029
Notes receivable from officers 294,000 353,000
Long term deposits 124,600 124,600
Total Assets $32,655,996 $32,511,104


LIABILITIES AND STOCKHOLDERS` EQUITY

Current liabilities:
Accounts payable $421,412 $629,080
Accrued expenses 1,755,079 1,552,661
Deferred revenue 2,433,240 1,792,505
Total current liabilities 4,609,731 3,974,246

Long-term deferred revenue 2,725,000 2,825,000

Stockholders` equity:
Undesignated preferred stock, $.01 par value: authorized
1,250,000 shares; no shares issued and outstanding - -

Common stock, $.01 par value: authorized 30,000,000
shares; issued 9,991,943 shares, respectively 99,919 99,919
Additional paid-in capital 31,829,531 31,959,316
Deferred compensation (474,982) (615,001)
Treasury stock, (at cost) 166,913 and 200,863 shares,
respectively (796,610) (959,870)
Accumulated deficit (5,336,593) (4,772,506)
Total stockholders` equity 25,321,265 25,711,858
Total Liabilities and Stockholders` Equity $32,655,996 $32,511,104







INCOME STATEMENTS (Unaudited)




Three months ended Three months ended

March 31,
March 31,

2000 1999 2000 1999
(As Restated)


Product revenue $2,620,833 $3,235,650 $2,620,833 $3,235,650
License revenue 100,000 100,000 100,000 100,000
Total revenue $2,720,833 $3,335,650 2,720,833 3,335,650
Cost of sales 1,232,968 1,708,171 1,232,968 1,708,171
Gross profit 1,487,865 1,627,479 1,487,865 1,627,479

Operating expenses:
Research and development 1,313,738 707,857 1,313,738 707,857
Selling, general and administrative 999,462 743,972 999,462 743,972
Total operating expenses 2,313,200 1,451,829 2,313,200 1,451,829
Income (loss) from operations -825,335 175,650 (825,335) 175,650

Interest income, net 261,248 302,150 261,248 302,150

Income (loss) before income taxes -564,087 477,800 (564,087) 477,800

Income taxes 0 21,979 - 21,979
Income (loss) before cumulative effect of change in account principle (564,087) 455,821 (564,087) 455,821
Cummulative effect of change in accounting principle 0 ######### - (3,625,000)
Net loss ($564,087) ######### ($564,087) ($3,169,179)


Basic earnings (loss) per share :

Income (loss) before cumulative effect of
change in accounting principle $0.00 $0.00 ($0.06) $0.05

Cumulative effect of change in accounting
principle 0.00 (0.36) 0.00 (0.38)

Net loss $0.00 $0.00 ($0.06) ($0.33)
Shares used for computing basic EPS 9,941,901 9,941,901 9,804,284 9,514,381

Diluted earnings (loss) per share :

Income (loss) before cumulative effect of
change in accounting principle $0.00 $0.00 ($0.06) $0.05

Cumulative effect of change in accounting
principle 0.00 (0.35) 0.00 (0.36)

Net loss $0.00 $0.00 ($0.06) ($0.31)
Shares used for computing diluted EPS 10,305,481 10,305,481 9,804,284 10,077,488

Contact:

Anika Therapeutics, Inc.
Douglas R. Potter, Chief Financial Officer
[phone]
Pondel Parsons & Wilkinson
Susan Klein, [phone]
Robert Whetstone, [phone]

[Maiestro]

Und nun der Text zum Rücktritt des Vorstandsmitgliedes!

Maiestro

[Maiestro]

ANIKA THERAPEUTICS DIRECTOR DONALDSON RESIGNS

Woburn, Mass.- May 9, 2000 - Anika Therapeutics, Inc. (Nasdaq: ANIK) today announced that Jonathan D. Donaldson has resigned from its board of directors. Donaldson, 50, chairman of Surgical Sealants, Inc., made the decision to leave Anika’s board to devote more time to other business and personal commitments, including additional responsibilities as a director of Emerson Hospital in Concord, Massachusetts.

J. Melville Engle, chairman, president and chief executive officer, said the company is initiating a search to find a replacement for Donaldson’s position on the board. “Jona has been one of the key contributors to Anika’s development since its inception. His insights and guidance will be missed. We wish him all the best in his other activities,” Engle said.

Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products and devices intended to promote the repair, protection and healing of bone, cartilage and soft tissue. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. In addition to ORTHOVISC® (not approved for sale in the U.S.), Anika markets HYVISC® in the U.S. for the treatment of equine osteoarthritis through Boehringer Ingelheim Vetmedica, Inc. and manufactures AMVISC® and AMVISC® Plus, HA viscoelastic products for ophthalmic surgery, for Bausch & Lomb Surgical. Therapies currently under development include INCERT®, a family of HA products designed to prevent post-surgical adhesions. Anika is also collaborating with Orquest, Inc. to manufacture Ossigel®, an injectable formulation of basic fibroblast growth factor combined with HA designed to accelerate the healing of bone fractures.
Contact:

Anika Therapeutics, Inc.
[phone]
Pondel Parsons & Wilkinson
Susan Klein, [phone]
Robert Whetstone, [phone]

[Maiestro]

Jetzt noch was allgemeines zu Anika Therapeutics, direkt von der Homepage!

http://www.anikatherapeutics.com

Maiestro

[Maiestro]

Therapeutic Products for Improved
Tissue Repair, Protection and Healing


Anika Therapeutics, Inc. develops, manufactures and commercializes therapeutic products and devices intended to repair, protect and heal bone, cartilage and soft tissues. These products are currently derived from hyaluronic acid ("HA"), a naturally-occurring, biocompatible polymer found throughout the body. As suggested in the literature, the unique biophysical and biochemical properties of HA appear to play an important role in a number of physiological functions such as the protection, coating and lubrication of soft tissues and joints, the maintenance of the structural integrity of tissues, and the transport of molecules to specific anatomical sites.

Anika has been developing and manufacturing HA and HA-based products since 1983 and is located in Woburn, Massachusetts. The company is also collaborating in the development of a product entailing a formulation of HA and a growth factor to accelerate bone fracture healing. Some of the company`s products are available in the US while others are available in international markets.


Anika is a leading manufacturer of highly purified, high molecular weight HA products. Extracting HA carefully from select, natural sources such as rooster combs, the company has developed a proprietary purification and formulation process used to consistently produce high quality, medical grade HA products. Anika`s HA products meet ISO 10993 biocompatibility requirements.

Anika focuses on the development of products to meet each unique medical application. Anika has established strong expertise in the production and formulation of the native HA molecule to preserve its integrity and to optimize its potential for therapeutic use, while packaging the HA products for convenient delivery. Anika produces a variety of products such as HA liquids, gels, powders and sponge-like membranes.

J. Melville Engle, 50, joined Anika Therapeutics as President and Chief Executive Officer in September 1996 after serving in the same capacity at U.S. Medical Products Inc., a manufacturer and distributor of orthopedic implants. He was named Chairman of Anika in February 1999. From 1980 to 1995, he was a senior executive with Allergan, Inc. overseeing sales and marketing of pharmaceutical eye and skin care products in the Americas region. He served as Allergan`s Chief Financial Officer from 1982 to 1985. Mr. Engle holds a master`s degree in business administration from the University of Southern California and a bachelor`s degree from the University of Colorado.
Edward Ross, Jr. is Vice President of Sales and Marketing. Mr. Ross, 43, joined Anika from Gliatech, Inc., where he also served as Vice President of Marketing and Sales and was responsible for worldwide commercialization of anti-adhesion and related therapeutic technologies. Before joining Gliatech in 1995, Mr. Ross was Business Director of biological reconstruction with Genetics Institute from 1992 to 1995. From 1985 to 1992, he held several marketing and management positions with the Zimmer division of Bristol-Myers Squibb Company. Prior to his experience with Zimmer, Mr. Ross held various sales and marketing positions with divisions of American Hospital Supply Corporation, Whittaker General Medical and G.D. Searle. Mr. Ross has a B.A. in Political Science from Dickinson College and an M.B.A. from the University of Rochester.
Charles H. Sherwood, Ph.D. is Vice President of Research and Development. Among other responsibilities, Dr. Sherwood oversees the design and engineering of manufacturing processes for new products and provides technical support to the Company`s manufacturing and development operations for existing products. Dr. Sherwood, 53, joined Anika from ophthalmic products manufacturer Chiron Vision, where he was senior director of medical device research and development. From 1982 to 1995, Dr. Sherwood was with IOLAB Corporation, a division of Johnson and Johnson, which was acquired by Chiron in 1995, serving most recently as executive director of research and development. Earlier, he worked on research and development programs with Hughes Aircraft Company and Lord Corporation. He has also served on the faculty of California State Polytechnic University, Pomona.

Dr. Sherwood holds a doctorate and master`s degree in polymer science and engineering from the University of Massachusetts, a bachelor`s degree in chemical engineering from Cornell University and a certificate in management from Claremont Graduate School. He holds three U.S. patents, has several patent applications pending and is the author of numerous scientific articles.
Michael R. Slater is Vice President, Operations. Mr. Slater, 53, most recently ran an independent regulatory affairs consulting practice. From 1995 to 1996, he was executive vice president, development operations for Waltham-based ImmuLogic Pharmaceutical Corporation where he was responsible for regulatory affairs, quality assurance, production, process development and formulation studies. For the 12 years prior, he was with Biogen, Inc., serving for 10 years as vice president, regulatory affairs. Mr. Slater began his corporate career with Hoechst Pharmaceuticals, U.K.

Mr. Slater holds a bachelor`s degree from the Metropolitan University of Leeds, England. Among his numerous professional qualifications and memberships, he was a member of the Biotechnology Advisory Committee and Subcommittee on FDA affairs of the Pharmaceutical Research Manufacturers` Association and a member of the FDA Committee of the Biotechnology Industry Association.

Douglas R. Potter, 49, was appointed Chief Financial Officer, Vice President of Finance, Treasurer and Clerk in April 2000, prior to which he served as Interim Chief Financial Officer of the Company on a consulting basis since February 2000. Mr. Potter previously served as Vice President and Chief Financial Officer of Dynamics Research Corporation, an information technology services provider, and SofTech, Inc., a software technology company. He was also employed for 10 years with the accounting firm PricewaterhouseCoopers. Mr. Potter is a certified public accountant and is a member of the Financial Executives Institute and the Treasurers Club of Boston. He has an M.B.A. from Boston University and a B.S. from Purdue University.

[Maiestro]

Hier noch was zu den Produkten von dem Unternehmen!

Maiestro

[Maiestro]

ORTHOVISC®
A highly purified, high molecular weight, high viscosity injectable form of hyaluronic acid (HA) intended to relieve pain and to improve joint mobility and range of motion in patients suffering from osteoarthritis (OA) of the knee. Currently, ORTHOVISC, a brand of sodium hyaluronate is not approved for use in the United States, but it is marketed and sold in Canada, Europe and other countries. ORTHOVISC is a localized injectable treatment for osteoarthritis of the knee which is an alternative to other injectable or oral treatments. ORTHOVISC is injected into the knee to restore the elasticity and viscosity of the synovial fluid.

Zimmer, a world leader in knee replacement products and a major division of Bristol-Myers Squibb, is the primary distributor for ORTHOVISC. The initial distribution agreement for exclusive rights to market the product in the United States, Canada and Asia was signed in 1997. The agreement was expanded in 1998 to include Europe and Latin America, and in 1999 Eastern Europe, the Middle East and Africa were added

ORTHOVISC is currently approved for sale and is marketed in Canada by Zimmer. In Europe ORTHOVISC has CE Marking which allows sale of the product as a "viscoelastic supplement" or a "replacement for synovial fluid in human joints." Zimmer, Inc. has launched the product in most of the major markets in Europe. The Zimmer European sales and marketing organization has been trained thoroughly, and highly qualified key field sales specialists have been hired to oversee the roll out in the various regions. Zimmer`s penetration strategy involves utilizing its broad distribution network and excellent physician relationships.

In other markets, ORTHOVISC is sold by Grupo Ferrer Internacional in Spain and Biomeks Pharmaceuticals in Turkey. Biomeks has sold the product successfully since 1995 and has supported numerous clinical studies of the product`s use in the treatment of osteoarthritis. In addition, Rafa Laboratories Ltd. is selling ORTHOVISC in Israel.

distributor.htmdistributor.htm

AMVISC®and AMVISC® PLUS
High molecular weight hyaluronic acid viscoelastic injectable (HA) solutions used to maintain eye shape and protect delicate tissues during cataract removal, corneal transplant and glaucoma surgery. Anika manufactures AMVISC and AMVISC Plus sodium hyaluronate for worldwide distribution by Bausch & Lomb Surgical, a division of Bausch & Lomb, Inc., which includes the acquisitions of Chiron Vision and Storz Ophthalmics. According to Anika estimates, the current worldwide market for ophthalmic viscoelastic products is $300 million. Anika believes that the demand for cataract surgery is expected to increase, as baby boomers age and average life expectancy increases, further fueling this market.

HYVISC®
A premium-grade, high molecular weight, injectable hyaluronic acid (HA) product developed by Anika currently used to treat osteoarthritis and lameness in racehorses. In February 1995, Anika entered into an exclusive marketing and distribution agreement for HYVISC sodium hyaluronate for the U.S. with Boehringer Ingelheim Vetmedica, a division of Boehringer Ingelheim International GmbH. Vetmedica has been selling HYVISC in the United States where the product is approved as a veterinary medicine.
http://www.vetmedica.com/

INCERT®

A family of bioabsorbable, cross-linked hyaluronic acid (HA) products that, when placed between tissues, is intended to act as a barrier to inhibit the formation of adhesions after surgery. Such adhesions can lead to female infertility, intestinal blockage and recurrent back pain, all of which often lead to costly secondary surgery in an attempt to correct such problems. Anika`s INCERT cross-linked HA anti-adhesion product shows promise based on preclinical animal models. Results from a recent animal study demonstrated INCERT`s ability to inhibit adhesions more effectively than a leading anti-adhesion product. Anika jointly owns a number of patents for the technology.


OSSIGEL®

A viscous formulation of hyaluronic acid (HA) and basic fibroblast growth factor (bFGF) designed to accelerate bone fracture healing. Orquest, Inc. is the owner, patent holder and developer of OSSIGEL. Anika holds exclusive rights to manufacture OSSIGEL for Orquest. According to Orquest, their preclinical studies suggest that OSSIGEL may improve fracture healing time by as much as 50%.

[Maiestro]

[Maiestro]

Etwa keine Meinungen zu diesem Wert oder seiner Entwicklung, das kann doch gar nicht sein!

Maiestro

[Maiestro]

Jetzt kommt macht schon! Irgendeine Meinung müssen doch einige hier haben.

Maiestro

:O:O:O:O:O:O:O:O
:O:O:O:O:O:O:O:O
:O:O:O:O:O:O:O:O
:O:O:O:O:O:O:O:O
:O:O:O:O:O:O:O:O
:O:O:O:O:O:O:O:O
:O:O:O:O:O:O:O:O
:O:O:O:O:O:O:O:O
:O:O:O:O:O:O:O:O
:O:O:O:O:O:O:O:O

[Jean_II]

Eins ist klar, charttechnisch siehts sehr interessant aus, wenn Wir diesen Herbst wieder einen richtigen Biotechrun erleben, werde die Zocker früher oder später auch wieder auf diesen Wert kommen und spätestens dann sollten ein paar Prozent drin sein!
Sollte Anika sich rehabilitieren, dann sind sogar einige hundert Prozent drin, werde nochmal etwas abwarten und mir die Firma mal ende August nochmal anschauen, dann schaun mer mal weiter...
Gruss Jean_II